Evidence for heterodimerization and functional interaction of the urotensin II and the angiotensin II type 1 receptors.

Angiotensin II Angiotensin II receptor type 1 Bioluminescence resonance energy transfer Heterodimerization Human urotensin II receptor Urotensin II Urotensin II-related peptide

Journal

Cellular signalling
ISSN: 1873-3913
Titre abrégé: Cell Signal
Pays: England
ID NLM: 8904683

Informations de publication

Date de publication:
21 Jan 2024
Historique:
received: 13 01 2024
accepted: 15 01 2024
medline: 24 1 2024
pubmed: 24 1 2024
entrez: 23 1 2024
Statut: aheadofprint

Résumé

Despite the observation of synergistic interactions between the urotensinergic and angiotensinergic systems, the interplay between the urotensin II receptor (hUT) and the angiotensin II type 1 receptor (hAT1R) in regulating cellular signaling remains incompletely understood. Notably, the putative interaction between hUT and hAT1R could engender reciprocal allosteric modulation of their signaling signatures, defining a unique role for these complexes in cardiovascular physiology and pathophysiology. Using a combination of co-immunoprecipitation, bioluminescence resonance energy transfer (BRET) and FlAsH BRET-based conformational biosensors, we first demonstrated the physical interaction between hUT and hAT1R. Next, to analyze how this functional interaction regulated proximal and distal hUT- and hAT1R-associated signaling pathways, we used BRET-based signaling biosensors and western blots to profile pathway-specific signaling in HEK 293 cells expressing hUT, hAT1R or both. We observed that hUT-hAT1R heterodimers triggered distinct signaling outcomes compared to their respective parent receptors alone. Notably, co-transfection of hUT and hAT1R has no impact on hUII-induced G

Identifiants

pubmed: 38262555
pii: S0898-6568(24)00024-X
doi: 10.1016/j.cellsig.2024.111056
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111056

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Hassan Nassour (H)

Institut National de la Recherche Scientifique, Centre Armand-Frappier Santé Biotechnologie, Université du Québec, Ville de Laval, QC, Canada.

Darlaine Pétrin (D)

Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada.

Dominic Devost (D)

Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada.

Etienne Billard (E)

Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada.

Rory Sleno (R)

Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada.

Terence E Hébert (TE)

Department of Pharmacology and Therapeutics, McGill University, Montréal, Canada. Electronic address: terence.hebert@mcgill.ca.

David Chatenet (D)

Institut National de la Recherche Scientifique, Centre Armand-Frappier Santé Biotechnologie, Université du Québec, Ville de Laval, QC, Canada. Electronic address: david.chatenet@inrs.ca.

Classifications MeSH